Stryker wins approval to buy Wright Medical Group from U.S. antitrust regulator
Stryker wins approval to buy Wright Medical Group from U.S. antitrust regulator
WASHINGTON, Nov 3 (Reuters) - Medical device maker Stryker Corp has won U.S. antitrust approval to buy Wright Medical Group on condition it sell certain assets, the Federal Trade Commission said on Tuesday.
The deal, which was valued at about $4 billion when it was announced late last year, was part of a series of consolidations in the medical device industry and would make Stryker one of the market leaders in implants for the treatment of bone fractures as well joint replacements.
To win approval for the deal, the companies agreed that Stryker would sell its businesses that make total ankle replacements, generally used to treat arthritis, and finger joint implants, used to treat advanced arthritis, to DJO Global , the FTC said.
Stryker did not immediately respond to a request for comment.
(Reporting by Diane Bartz
Editing by Bill Berkrot)
((Diane.Bartz@thomsonreuters.com; 1 202 898 8313;)
路透華盛頓11月3日電-美國聯邦貿易委員會(Federal Trade Commission)週二表示，醫療器械製造商Stryker Corp(ST.N：行情)已獲得美國反壟斷批准，將收購Wright Medical Group，條件是該集團出售某些資產.這筆交易在去年年底宣佈時價值約為40億美元，是醫療器械行業一系列整合的一部分，將使Stryker成為治療骨折和關節置換植入物領域的市場領先者之一。FTC表示，為了贏得交易的批准，兩家公司同意將Stryker將其生產腳踝全置換(通常用於治療關節炎)和手指關節植入物(用於治療晚期關節炎)的業務出售給DJO Global。Stryker沒有立即回覆記者的置評請求。(Diane Bartz報道)編輯：比爾·伯克羅(Bill Berkrott)(Diane.Bartz@thomsonreurs.com；1 202 898 8313；)
譯文內容由第三人軟體翻譯。